Hambrecht & Quist Capital Management »

89bio shares owned by Hambrecht & Quist Capital Management

Quarter-by-quarter ownership of 89bio (ETNB) shares owned by Hambrecht & Quist Capital Management from 13F filings

Historical chart of Hambrecht & Quist Capital Management investment in 89bio

Tip: Access up to 7 years of quarterly data

All positions including 89bio held by Hambrecht & Quist Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 89bio by Hambrecht & Quist Capital Management

Quarter filed Position value Share count Share price at filing
2023-06-30 $2.0M 106k 18.95
2023-03-31 $1.6M 106k 15.23

More positions owned by Hambrecht & Quist Capital Management

Amgen Common (AMGN)
Johnson & Johnson Common (JNJ)
Gilead Sciences Common (GILD)
Regeneron Pharmaceuticals Common (REGN)
Vertex Pharmaceuticals Common (VRTX)
Eli Lilly and Company Common (LLY)
Unitedhealth Group Common (UNH)
Merck & Co Common (MRK)
AbbVie Common (ABBV)
Biogen Common (BIIB)
AstraZeneca Sponsored ADR (AZN)
Illumina Common (ILMN)
Abbott Laboratories Common (ABT)
Pfizer Common (PFE)
Thermo Fisher Scientific Common (TMO)

View all positions for Hambrecht & Quist Capital Management

Top funds holding 89bio

RA Capital Management
Henderson Group
Vanguard Group
BVF
Holocene Advisors
Laurion Capital Management
Citadel Advisors
Frazier Life Sciences Management
Redmile Group
Federated Investors
Westfield Capital Management Company
Superstring Capital Management
Franklin Resources
Orchard Capital Managment
Caption Management

View all funds holding 89bio